Related Experiment Video

Updated: Dec 8, 2025

Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence
10:29

Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence

Published on: August 14, 2019

10.9K

TILs and Anti-PD1 Therapy: An Alternative Combination Therapy for PDL1 Negative Metastatic Cervical Cancer

Huanhuan Yin1, Wei Guo1, Xiangling Sun1

  • 1Department of Obstetrics, Luoyang Central Hospital Affiliated to Zhengzhou University, Luoyang 471009, China.

Journal of Immunology Research
|September 23, 2020
PubMed
Abstract

Insights

Tumor-infiltrating lymphocytes (TILs) combined with anti-PD1 therapy show promise for metastatic cervical cancer. This combination significantly improved progression-free and overall survival in patients with low MSI and PDL1 expression.

Area of Science:

  • Oncology
  • Immunotherapy
  • Cervical Cancer Research

Background:

  • Investigated efficacy of tumor-infiltrating lymphocytes (TILs) and anti-PD1 combination therapy.
  • Focused on patients with metastatic cervical cancer, specifically those with low microsatellite instability (MSI) expression and PDL1-negative status.

Purpose of the Study:

  • To evaluate the therapeutic efficacy of TILs and anti-PD1 combination therapy.
  • To identify prognostic factors for metastatic cervical cancer in the studied patient cohort.

Main Methods:

  • Enrolled 80 patients receiving TILs and anti-PD1 combination therapy.
  • Assessed progression-free survival (PFS) and overall survival (OS) using Kaplan-Meier analysis.
  • Performed univariate and multivariate analyses to determine predictive factors for prognosis.

Main Results:

  • Achieved an objective response rate of 25%.
  • Reported a median progression-free survival (mPFS) of 6.1 months and a median overall survival (mOS) of 11.3 months.
  • Found that TIL characteristics, HPV infection, and post-therapy fever influenced therapeutic efficacy.

Conclusions:

  • The combination therapy of TILs and anti-PD1 significantly enhances the prognosis for patients with metastatic cervical cancer.
  • Highlights the potential of this combination therapy for specific subgroups of cervical cancer patients.

More Related Videos

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology07:04

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

Published on: May 2, 2025

904
Using 22C3 Anti-PD-L1 Antibody Concentrate on Biopsy and Cytology Samples from Non-small Cell Lung Cancer Patients07:43

Using 22C3 Anti-PD-L1 Antibody Concentrate on Biopsy and Cytology Samples from Non-small Cell Lung Cancer Patients

Published on: September 25, 2018

10.9K

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
1.3K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.7K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.4K